Sanoptis
Andrea Masotti is an experienced professional in mergers and acquisitions, currently serving as the Director of M&A and Head of M&A for Switzerland, Italy, and Spain at Sanoptis since February 2023. Prior to this role, Andrea worked at Sulzer as a Manager in Strategy and Corporate Development (M&A) and at Lincoln International as an Associate and Analyst in Investment Banking focused on M&A. Additional experience includes an Analyst position at Redalpine Venture Partners AG and a Financial Analyst role at Switzerland Global Enterprise. Andrea began a career in consulting at Accenture and gained early experience as a Credit Analyst at Credit Suisse. Educational qualifications include a Master of Arts in Management and Economics from the University of Zurich and a Bachelor of Science in Management from HEC Lausanne.
This person is not in any teams
This person is not in any offices
Sanoptis
1 followers
Sanoptis is a leading network of modern ophthalmology clinics across Europe, with over 300 locations. We are committed to providing the highest standard of ophthalmological care for our patients. Our dedication to excellence, innovation, and collaborative partnerships with doctors has positioned us as industry leaders. Our vision at Sanoptis is to ensure that everyone has access to the best ophthalmological care, enhancing their well-being and quality of life through cutting-edge diagnostics and therapeutic solutions. Our success is driven by our highly skilled professionals in ophthalmology and healthcare management. We foster an environment that values expertise, creativity, and dedication, empowering our employees to drive our company ahead. As we continuously push the boundaries of ophthalmological care, we actively seek exceptional talent and individuals who can contribute their expertise to our mission. We are committed to nurturing the next generation of doctors and developing medical talent within our clinics, offering a comprehensive range of ophthalmology treatments. Join our dynamic team at Sanoptis and help us shape the future of ophthalmology, transforming lives along the way.